Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J. , Nov. 28, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor
View HTML
Toggle Summary SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference
JERSEY CITY, N.J. , Nov. 22, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 29th Annual Piper Jaffray
View HTML
Toggle Summary SCYNEXIS Appoints Scott Sukenick as General Counsel
- Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) - JERSEY CITY, N.J. , Nov. 16, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced the
View HTML
Toggle Summary SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
Ongoing Dosing of Patients in Clinical Studies for Two Indications New Data Publications Support the Potential Use of SCY-078 in Multiple New Indications JERSEY CITY, N.J. , Nov. 7, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective
View HTML
Toggle Summary SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
In vivo and in vitro data show SCY-078’s favorable profile and potential therapeutic benefit JERSEY CITY, N.J. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening
View HTML
Toggle Summary SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
Additional SCY-078 Posters to be Presented at 8 th Trends in Medical Mycology Pre-clinical data further highlight SCY-078’s broad spectrum of activity and differentiated attributes JERSEY CITY, N.J. , Sept. 27, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor
View HTML
Toggle Summary "THINK FUNGUS" - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
The first Fungal Disease Awareness Week is designed to increase awareness about fungal diseases, which can cause severe illness but frequently go undiagnosed
View HTML
Toggle Summary SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
Potent anti-Candida activity shown in vaginal acidic pH and high penetration into vaginal tissue Positive efficacy data reported from proof-of-concept Phase 2 VVC study JERSEY CITY, N.J., Aug. 14, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative
View HTML
Toggle Summary SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
Dosing Initiated in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis Recent Data Publications Showcase Broad and Potent Activity of SCY-078 Against Multiple Fungal Species Including Candida auris JERSEY CITY, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML